Last Update 03 Mar 26

CHRS: Upcoming Readouts And New Collaboration Will Shape Oncology Pipeline Outlook

Analysts have kept their average $6.75 price target on Coherus Oncology steady, as recent bullish coverage and Outperform initiations are balanced by updated assumptions that include a lower projected profit margin and a higher future P/E multiple.

Analyst Commentary

Bullish Takeaways

Bullish analysts highlight that fresh Outperform initiations signal confidence that the current share price already reflects more cautious margin and P/E assumptions.
They view upcoming clinical readouts as key potential catalysts that could help justify the higher future P/E multiple embedded in updated models.
Supportive coverage suggests that, even with lower projected profitability, the company’s oncology portfolio is seen as having enough potential to keep the stock aligned with the existing US$6.75 target.
Positive ratings are framed around execution on the development pipeline, with the view that delivering clinical milestones could help support valuation despite more conservative margin forecasts.

Bearish Takeaways

More cautious analysts point to the revised lower profit margin assumptions as a reminder that execution risk on costs and commercialization remains a key swing factor for equity value.
The use of a higher future P/E multiple in some models raises questions about how much of the potential upside from upcoming readouts is already reflected in the stock.
There is concern that if clinical or regulatory timelines slip, the case for maintaining both an Outperform rating and the US$6.75 target could weaken, given the less generous margin outlook.
Some see limited room for error on both clinical execution and capital allocation, since the valuation now relies more heavily on future earnings expectations rather than near term profitability.

What's in the News

Coherus Oncology completed a follow on equity offering of US$50.05 million, issuing 28,600,000 common shares at US$1.75 per share with a US$0.105 discount per share (Key Developments).
The company filed additional follow on equity offerings, including an at the market program of US$64.880054 million in common stock (Key Developments).
Multiple securities, including common stock, stock options, warrants and convertible notes, are subject to lock up agreements running from 12 February 2026 to 14 April 2026, limiting sales by directors, executive officers and certain affiliated stockholders without underwriter consent (Key Developments).
Coherus Oncology announced a clinical supply agreement with Janssen Research & Development to evaluate tagmokitug (CHS-114) with pasritamig in a Phase 1b trial in metastatic castration resistant prostate cancer, with each company retaining commercial rights to its own compound (Key Developments).
The company was added to the NASDAQ Biotechnology Index, reflecting its inclusion in a major biotechnology benchmark (Key Developments).

Valuation Changes

Fair Value: The model fair value remains at $6.75, with no change from the prior estimate.
Discount Rate: The discount rate has risen slightly from 7.40% to about 7.44%, implying a marginally higher required return in the updated assumptions.
Revenue Growth: The long term revenue growth assumption is unchanged at about 13.53% annual decline, indicating a consistent view of top line trends.
Net Profit Margin: The projected net profit margin has fallen from 16.94% to 10.90%, reflecting a more cautious stance on future profitability.
Future P/E: The future P/E multiple assumption has increased from 37.40x to about 58.21x, suggesting that a larger share of the valuation now rests on expected earnings further out.

1 view

Key Takeaways

Advancement of clinical pipeline and increased physician adoption are expected to drive strong revenue growth and strengthen market position in high-need oncology indications.
Strategic global partnerships and operational efficiency initiatives support improved profitability, lower financial risk, and long-term sustainable earnings expansion.
Intense competition, product concentration risk, commercialization challenges, rising costs, and dependence on partnerships threaten Coherus Oncology's revenue growth, profitability, and financial stability.

Catalysts

About Coherus Oncology

A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.What are the underlying business or industry changes driving this perspective?

Significant upcoming clinical data readouts for CHS-114 (CCR8 Treg depleter) and casdozokitug (anti-IL-27) in 2026 target high unmet-need solid tumor indications (head and neck, gastric, esophageal, liver, lung cancers) driven by the aging population and rising cancer incidence globally; successful results could unlock new, large revenue streams and accelerate future growth.
Enhanced commercial execution for LOQTORZI, with recent NCCN guideline upgrades and expanding physician adoption (particularly community oncologists), positions the business to capture a growing share of a $150–200M U.S. NPC market, with potential to materially increase near-term revenues and support a steady ramp to peak sales by 2028.
Multiple pipeline assets are paired with LOQTORZI in trials, increasing the likelihood that every successful new indication simultaneously expands LOQTORZI's addressable market, enabling both top-line revenue growth and improved product mix, which should boost future net margins.
A capital-efficient strategy of forming global partnerships and ex-U.S. licensing deals for novel immuno-oncology assets (leveraging rising global health care spending and improved access) provides nondilutive cash inflows, offsets development costs, and supports sustainable long-term earnings growth.
The company's strengthened balance sheet and ongoing operational cost reductions following divestiture (including $30M+ in annualized cost savings) improve profitability and extend cash runway through key data catalysts, supporting margin expansion and reducing risk to future earnings.

Coherus Oncology Earnings and Revenue Growth

Coherus Oncology Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Coherus Oncology's revenue will decrease by 21.9% annually over the next 3 years.
Analysts are not forecasting that Coherus Oncology will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Coherus Oncology's profit margin will increase from 21.7% to the average US Biotechs industry of 16.1% in 3 years.
If Coherus Oncology's profit margin were to converge on the industry average, you could expect earnings to reach $20.8 million (and earnings per share of $0.18) by about September 2028, down from $59.1 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 33.0x on those 2028 earnings, up from 2.5x today. This future PE is greater than the current PE for the US Biotechs industry at 15.5x.
Analysts expect the number of shares outstanding to grow by 0.88% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Coherus Oncology Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Intense competition in the immuno-oncology and CCR8/Treg depleter space, with numerous large pharma players and multiple upcoming clinical data readouts from competitors in 2026, may erode Coherus Oncology's first-mover advantage or lead to market share dilution, thereby constraining long-term revenue growth.
Heavy reliance on a narrow product portfolio, particularly LOQTORZI and near-term pipeline assets, exposes the company to significant revenue concentration risk; setbacks such as unfavorable clinical data, regulatory delays, or failure to secure label expansions could cause revenue, earnings, and net margin declines.
Extended commercialization ramp in the large community oncology segment, where physician adoption of new guidelines and treatment protocols is slow and fragmented, may delay peak revenue realization and impact both short
and long-term sales trajectories.
Potential increased operating costs and resource needs to simultaneously support broad clinical development, multiple regional trials, and a wider commercial push, especially against better-capitalized competitors, could pressure net margins and delay break-even or profitability inflection points.
Dependence on external partnerships and ex-U.S. licensing for pipeline validation and nondilutive funding carries execution risks; failure to secure favorable deals in key markets or delays in partner development efforts would increase the company's funding needs and could limit long-term earnings and financial flexibility.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $4.7 for Coherus Oncology based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $7.0, and the most bearish reporting a price target of just $1.1.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $129.7 million, earnings will come to $20.8 million, and it would be trading on a PE ratio of 33.0x, assuming you use a discount rate of 7.1%.
Given the current share price of $1.26, the analyst price target of $4.7 is 73.2% higher. Despite analysts expecting the underlying buisness to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Coherus Oncology?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Upcoming Clinical Data Will Reshape Immuno-Oncology Amid Uncertainties